ITP
MCID: THR001
MIFTS: 55

Thrombocytopenia Due to Platelet Alloimmunization (ITP)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards integrated aliases for Thrombocytopenia Due to Platelet Alloimmunization:

Name: Thrombocytopenia Due to Platelet Alloimmunization 12 15 72
Autoimmune Thrombocytopenia 25 59 29 55 72
Immune Thrombocytopenia 12 75 53 25 15
Immune Thrombocytopenic Purpura 25 72
Thrombocytopenia Due to Immune Destruction 12
Idiopathic Thrombocytopenic Purpura 25
Autoimmune Thrombocytopenic Purpura 25
Auto-Immune Thrombocytopenia 12
Werlhof Disease 25
Itp 25

Classifications:



External Ids:

Disease Ontology 12 DOID:1587
NCIt 50 C3991
SNOMED-CT 68 2897005
ICD10 via Orphanet 34 D69.3
UMLS via Orphanet 73 C0242584
Orphanet 59 ORPHA71203
UMLS 72 C0242584 C0272286 C0398650

Summaries for Thrombocytopenia Due to Platelet Alloimmunization

Genetics Home Reference : 25 Immune thrombocytopenia is a disorder characterized by a blood abnormality called thrombocytopenia, which is a shortage of blood cell fragments called platelets that are needed for normal blood clotting. Affected individuals can develop red or purple spots on the skin caused by bleeding just under the skin's surface. Small spots of bleeding under the skin are called purpura and larger spots are called ecchymoses. People with immune thrombocytopenia can have significant bleeding episodes, such as nose bleeds (epistaxis) or bleeding in the moist lining (mucosae) of the mouth. In severe cases, individuals may have gastrointestinal bleeding or blood in the urine or stool, or heavy and prolonged menstrual bleeding (menorrhagia). In very rare instances, bleeding inside the skull (intracranial hemorrhage) can occur, which can be life-threatening. A greater reduction in platelet numbers is often associated with more frequent bleeding episodes and an increased risk of severe bleeding. While immune thrombocytopenia can be diagnosed at any age, there are two periods when the condition is most likely to develop: early childhood and late adulthood. In children, the reduction in platelets is often sudden, but platelet levels usually return to normal levels within weeks to months. Immune thrombocytopenia in children is often preceded by a minor infection, such as an upper respiratory infection, but the relationship between the infection and immune thrombocytopenia is not clear. In adults, the development of immune thrombocytopenia is usually gradual and the condition tends to persist throughout life.

MalaCards based summary : Thrombocytopenia Due to Platelet Alloimmunization, also known as autoimmune thrombocytopenia, is related to amegakaryocytic thrombocytopenia, congenital and purpura. An important gene associated with Thrombocytopenia Due to Platelet Alloimmunization is IFNG-AS1 (IFNG Antisense RNA 1), and among its related pathways/superpathways are Akt Signaling and Response to elevated platelet cytosolic Ca2+. The drugs Prednisone and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are hematopoietic system and cellular

Wikipedia : 75 Immune thrombocytopenia purpura (ITP), also known as idiopathic thrombocytopenic purpura, is a type of... more...

Related Diseases for Thrombocytopenia Due to Platelet Alloimmunization

Diseases in the Thrombocytopenia family:

Thrombocytopenia 2 Thrombocytopenia 3
Thrombocytopenia 1 Thrombocytopenia 4
Thrombocytopenia 5 Thrombocytopenia 6
Acquired Thrombocytopenia Thrombocytopenia Due to Platelet Alloimmunization
Primary Thrombocytopenia

Diseases related to Thrombocytopenia Due to Platelet Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 868)
# Related Disease Score Top Affiliating Genes
1 amegakaryocytic thrombocytopenia, congenital 32.8 THPO MPL
2 purpura 32.4 THPO MPL ITGB3 ITGA2B
3 thrombocytopenic purpura, autoimmune 31.6 THPO SELP MPL ITGB3 ITGA2B FCGR2C
4 thrombocytopenia 30.9 THPO MPL ITGB3 ITGA2B ITGA2 GP9
5 thrombocytosis 30.8 THPO SELP MPL
6 thrombocytopenia 3 30.7 THPO MPL
7 hemorrhagic disease 30.6 THPO MPL ITGA2B
8 heparin-induced thrombocytopenia 30.6 FCGR2A CD40LG
9 fetal and neonatal alloimmune thrombocytopenia 30.2 ITGB3 ITGA2B ITGA2
10 hypersplenism 30.0 THPO CD4
11 polycythemia vera 29.9 THPO SELP MPL ITGB3
12 essential thrombocythemia 29.7 THPO SELP MPL ITGB3 ITGA2B
13 bernard-soulier syndrome 29.4 THPO ITGB3 ITGA2B ITGA2 GP9
14 thrombasthenia 29.3 SELP ITGB3 ITGA2B ITGA2 GP9
15 gray platelet syndrome 29.3 SELP GP9 CD40LG
16 myocardial infarction 29.2 SELP ITGB3 ITGA2B ITGA2 CD40LG
17 blood platelet disease 29.1 THPO SELP MPL ITGB3 ITGA2B GP9
18 glanzmann thrombasthenia 29.0 SELP ITGB3 ITGA2B ITGA2 GP9
19 common variable immunodeficiency 28.9 FCGRT CD40LG CD19
20 primary thrombocytopenia 27.9 THPO SELP MPL ITGB3 ITGA2B ITGA2
21 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.3
22 sea-blue histiocyte disease 11.8
23 immunodeficiency, common variable, 8, with autoimmunity 11.7
24 ras-associated autoimmune leukoproliferative disorder 11.5
25 inosine triphosphatase deficiency 11.5
26 spondyloenchondrodysplasia 11.5
27 purine nucleoside phosphorylase deficiency 11.2
28 autoimmune lymphoproliferative syndrome, type v 11.2
29 autoimmune lymphoproliferative syndrome due to ctla4 haploinsuffiency 11.2
30 antiphospholipid syndrome, familial 11.1
31 autoimmune disease 10.8
32 helicobacter pylori infection 10.5
33 thrombocythemia 1 10.5 THPO MPL
34 hemolytic anemia 10.5
35 immune deficiency disease 10.5
36 lymphocytic leukemia 10.5
37 dyskeratosis congenita, autosomal dominant 6 10.5 THPO MPL
38 thrombotic thrombocytopenic purpura 10.5
39 bleeding disorder, platelet-type, 16 10.5 ITGB3 ITGA2B
40 ulcerative colitis 10.4
41 rubella 10.4
42 splenomegaly 10.4
43 aspirin resistance 10.4 ITGB3 ITGA2
44 mumps 10.4
45 acquired thrombocytopenia 10.4
46 autosomal dominant macrothrombocytopenia 10.4 ITGB3 ITGA2B
47 anemia, autoimmune hemolytic 10.4
48 hepatitis c virus 10.4
49 colitis 10.4
50 evans' syndrome 10.4

Graphical network of the top 20 diseases related to Thrombocytopenia Due to Platelet Alloimmunization:



Diseases related to Thrombocytopenia Due to Platelet Alloimmunization

Symptoms & Phenotypes for Thrombocytopenia Due to Platelet Alloimmunization

MGI Mouse Phenotypes related to Thrombocytopenia Due to Platelet Alloimmunization:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 CCR6 CD19 CD4 CD40LG FCGR2A FCGR2B
2 cellular MP:0005384 9.91 CD19 CD4 CD40LG FCGR2B ITGA2 ITGA2B
3 homeostasis/metabolism MP:0005376 9.73 CCR6 CD19 CD4 CD40LG FCGR2B FCGRT
4 immune system MP:0005387 9.4 CCR6 CD19 CD4 CD40LG FCGR2A FCGR2B

Drugs & Therapeutics for Thrombocytopenia Due to Platelet Alloimmunization

Drugs for Thrombocytopenia Due to Platelet Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Azathioprine Approved Phase 4 446-86-6 2265
3
Dexlansoprazole Approved, Investigational Phase 4 103577-45-3, 138530-94-6 9578005
4
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
5
Vincristine Approved, Investigational Phase 4 57-22-7, 2068-78-2 5978
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Hydroxychloroquine Approved Phase 4 118-42-3 3652
8
Morphine Approved, Investigational Phase 4 57-27-2 5288826
9
glycyrrhizin Approved, Experimental Phase 4 1405-86-3 3495
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
11
alemtuzumab Approved, Investigational Phase 4 216503-57-0
12
Clarithromycin Approved Phase 4 81103-11-9 84029
13
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
14
Enoxolone Investigational Phase 4 471-53-4 18526330
15 Antiprotozoal Agents Phase 4
16 Antiparasitic Agents Phase 4
17 Antimalarials Phase 4
18 Antineoplastic Agents, Phytogenic Phase 4
19 Tubulin Modulators Phase 4
20 Antimitotic Agents Phase 4
21 Antilymphocyte Serum Phase 4
22 Calcineurin Inhibitors Phase 4
23 Calcium, Dietary Phase 4
24 Bone Density Conservation Agents Phase 4
25 Cariostatic Agents Phase 4
26
Tin Phase 4 7440-31-5
27 Tin Fluorides Phase 4
28 Fluorides Phase 4
29 Pharmaceutical Solutions Phase 4
30 Antineoplastic Agents, Immunological Phase 4
31 Immunoglobulins, Intravenous Phase 4
32 gamma-Globulins Phase 4
33 Rho(D) Immune Globulin Phase 4
34 Cytochrome P-450 CYP3A Inhibitors Phase 4
35 Cytochrome P-450 Enzyme Inhibitors Phase 4
36
leucovorin Approved Phase 3 58-05-9 143 6006
37
Selenium Approved, Investigational, Vet_approved Phase 2, Phase 3 7782-49-2
38
Dapsone Approved, Investigational Phase 3 80-08-0 2955
39
Acetaminophen Approved Phase 3 103-90-2 1983
40
Chlorpheniramine Approved Phase 3 132-22-9, 113-92-8 2725
41
Histamine Approved, Investigational Phase 3 51-45-6 774
42
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
43
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
44
Pantoprazole Approved Phase 3 102625-70-7 4679
45
Oseltamivir Approved Phase 3 204255-11-8, 196618-13-0 65028
46
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
47
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
48
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
50
Decitabine Approved, Investigational Phase 3 2353-33-5 451668

Interventional clinical trials:

(show top 50) (show all 314)
# Name Status NCT ID Phase Drugs
1 A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP) Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
2 A Phase IV, Open-label, Prospective, Multicenter Study of the Efficacy and Safety of Recombinant Human Thrombopoietin Injection (rHuTPO, TPIAO)on Platelet Engraftment in Allogeneic Hematopoietic Stem Cell Transplantation in China Unknown status NCT01379391 Phase 4 Recombinant Human Thrombopoietin (rHTPO)
3 A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
4 Assessment of Platelet Function in Patients With Chronic Autoimmune Thrombocytopenic Purpura (cAITP) Treated With the Thrombopoietin Receptor (MPL) Agonist Eltrombopag. Completed NCT00888901 Phase 4 eltrombopag;corticosteroids (Aprednislon)
5 Helicobacter Pylori Infection in Children With Chronic Idiopathic Thrombocytopenic Purpura Completed NCT00467571 Phase 4 lansoprazole, clarithromycin, amoxycillin
6 A Longitudinal 2-year Bone Marrow Study of Eltrombopag Olamine (SB-497115-GR) in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT01098487 Phase 4 Eltrombopag olamine
7 An Open-label, Prospective, Multicenter Study to Investigate the Specificity of in Vivo Antibody Binding to Red Blood Cells in Subjects With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With IgPro10 (Privigen®) Who Have Shown Signs of Hemolysis Completed NCT01390649 Phase 4
8 A Randomized Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection Completed NCT01219764 Phase 4 Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
9 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
10 The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia Completed NCT03258866 Phase 4 Rituximab;Rituximab
11 High-dose Dexamethasone and Conventional Dose Prednisone, for the First-line Treatment of Adults With ITP: a Multicenter, Randomized Controlled, Clinical Trial Completed NCT01356511 Phase 4 Prednisone;Dexamethasone
12 Collection of Blood Samples From Patients With Relapsing Forms of Multiple Sclerosis (RMS) Who Have Developed Immune Thrombocytopenic Purpura (ITP) After LEMTRADA® Treatment Recruiting NCT03784898 Phase 4
13 Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag Recruiting NCT01957176 Phase 4 ELT
14 Treatment With Thrombopoietin Mimetic Plus Immunosuppressive Therapy in Egyptian Patients With Aplastic Anaemia Recruiting NCT03896971 Phase 4 Combination of thrombopoietin mimetic and cyclosporin A
15 A Single-center Prospective Randomized Study of Atorvastatin in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03692754 Phase 4 Atorvastatin 20mg;Atorvastatin 10mg
16 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency) Recruiting NCT03201848 Phase 4 Placebo;Huaiqihuang Granule
17 A Single-center Prospective Randomized Study of Glycyrrhetinic Acid Combined With Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP) Recruiting NCT03998982 Phase 4 Glycyrrhetinic Acid;Dexamethasone
18 Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia Recruiting NCT03243656 Phase 4 Eltrombopag
19 Efficacy and Safety of rhTPO and Eltrombopag in the Treatment of Chinese Adults With Primary Immune Thrombocytopenia (ITP):a Multicenter, Double-blind, Randomized, Controlled Trial Recruiting NCT03771378 Phase 4 rhTPO;eltrombopag
20 Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study Recruiting NCT03119974 Phase 4 Tpo-RA discontinuation
21 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
22 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
23 Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim Active, not recruiting NCT02760251 Phase 4 romiplostim
24 A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409) Active, not recruiting NCT02255656 Phase 4 alemtuzumab GZ402673
25 Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura Not yet recruiting NCT03172676 Phase 4 Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.;Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.;Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month
26 Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) Not yet recruiting NCT03866798 Phase 4
27 Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial Withdrawn NCT02642380 Phase 4 Dexamethasone (4 cycles);Dexamethasone (1 cycle)
28 AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION Withdrawn NCT02045251 Phase 4 Pylera based reduced regimen
29 Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes Unknown status NCT02877212 Phase 3 Eltrombopag
30 Thrombocytopenia in Gestational Period Unknown status NCT02751593 Phase 2, Phase 3 Dexamethasone
31 Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy Unknown status NCT01763658 Phase 2, Phase 3 Antox tablets(Mepaco)
32 A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy Unknown status NCT02391272 Phase 3 rhTPO
33 Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial Unknown status NCT02270801 Phase 3 rhTPO
34 Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia Unknown status NCT02627417 Phase 3 Dapsone (Disulone®);Prednisone (Cortancyl®) alone followed by monitoring and "standard of care";Prednisone (Cortancyl®)
35 A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients Unknown status NCT02834468 Phase 3 DEX Combined With RTX, CSA and IVIG
36 A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia Unknown status NCT01805648 Phase 3 rhTPO
37 Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Safety and Efficacy of Low-Dose Glucocorticoid Infusion in Acute Respiratory Distress Syndrome (ARDS) Unknown status NCT00562835 Phase 2, Phase 3 Methylprednisolone
38 An Open-label, Multicenter Study on the Efficacy and Safety of IgPro10 in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Completed NCT00168038 Phase 3
39 A Two Part, Double-blind, Randomized, Placebo-controlled and Open-label Study to Investigate the Efficacy, Safety and Tolerability of Eltrombopag, a Thrombopoietin Receptor Agonist, in Pediatric Patients With Previously Treated Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). PETIT2: Eltrombopag in PEdiatric Patients With Thrombocytopenia From ITP Completed NCT01520909 Phase 3 Eltrombopag;Placebo
40 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Completed NCT00508820 Phase 3
41 Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP). Completed NCT02063789 Phase 3 Human immunoglobulin intravenous
42 Rituximab as Second Line Treatment for ITP; A Multicenter, Randomized, Double Blind, Placebo-controlled, Phase III Study. "The RITP Study" Completed NCT00344149 Phase 3 Rituximab (Mabthera)
43 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00415532 Phase 3 Medical Standard of Care for ITP
44 An Open Label Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune (Idiopathic) Thrombocytopenia Purpura (ITP) Completed NCT01071954 Phase 3
45 Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura Completed NCT00699140 Phase 3
46 Clinical Study to Evaluate the Efficacy and Safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in Adults Completed NCT00426270 Phase 3 Octagam 10%
47 A Multi-center, Prospective, Open-label, Clinical Trial to Assess the Safety and the Efficacy of a New Intravenous Immune Globulin (IGIV3I Grifols 10%) in Patients With Idiopathic (Immune) Thrombocytopenic Purpura Completed NCT00511147 Phase 3
48 A Phase 3 Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP) Completed NCT01444417 Phase 3 Romiplostim;Placebo
49 Randomized Study of the Treatment of Primary Immune Thrombocytopenic Purpura (ITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone Versus High-dose Dexamethasone. Completed NCT00657410 Phase 3 dexamethasone;prednisone
50 A Randomized, Double Blind, Placebo Controlled Phase 3 Study Evaluating the Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura Completed NCT00603642 Phase 3 Placebo;AMG 531

Search NIH Clinical Center for Thrombocytopenia Due to Platelet Alloimmunization

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Azathioprine
Cyclophosphamide
Immunoglobulins, Intravenous
Intramuscular immunoglobulin
Rho(D) Immune Globulin, human
Venoglobulin-I
Vinblastine
Vinblastine Sulfate

Genetic Tests for Thrombocytopenia Due to Platelet Alloimmunization

Genetic tests related to Thrombocytopenia Due to Platelet Alloimmunization:

# Genetic test Affiliating Genes
1 Autoimmune Thrombocytopenia 29 FCGR2C

Anatomical Context for Thrombocytopenia Due to Platelet Alloimmunization

MalaCards organs/tissues related to Thrombocytopenia Due to Platelet Alloimmunization:

41
Bone, Bone Marrow, T Cells, B Cells, Spleen, Liver, Testes

Publications for Thrombocytopenia Due to Platelet Alloimmunization

Articles related to Thrombocytopenia Due to Platelet Alloimmunization:

(show top 50) (show all 3157)
# Title Authors PMID Year
1
Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. 38
30661482 2019
2
Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study. 38
30355275 2019
3
Association of cytotoxic T-lymphocyte antigen 4 gene with immune thrombocytopenia in Chinese Han children. 38
30319055 2019
4
The imbalance between regulatory memory B cells reveals possible pathogenesis involvement in pediatric immune thrombocytopenia. 38
31142214 2019
5
Thrombopoietin receptor agonists as second-line therapy in splenectomy-eligible persistent immune thrombocytopenia: a case series. 38
31259778 2019
6
Macrothrombocytopenia associated with a rare GFI1B missense variant confounding the presentation of immune thrombocytopenia. 38
31207059 2019
7
Complete remission of immune thrombocytopenia in a 30-year old woman after excision of a right atrial myxoma. 38
31388989 2019
8
All-trans retinoic acid protects mesenchymal stem cells from immune thrombocytopenia by regulating the complement-interleukin-1β loop. 38
30679324 2019
9
Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. 38
30950041 2019
10
Vincristine-loaded platelets coated with anti-CD41 mAbs: a new macrophage targeting proposal for the treatment of immune thrombocytopenia. 38
31414106 2019
11
[Relationship of Peripheral Blood IL-37 Expression with T Lymphocytes Subsets and NK Cells in Patients with Primary Immune Thrombocytopenia]. 38
31418380 2019
12
[Predictive Effect of Platelet Activation Index Expression before and after Adenosine Bisphosphate Activation on Bleeding Risk in ITP Patients]. 38
31418386 2019
13
Next-generation Fc receptor-targeting biologics for autoimmune diseases. 38
31404703 2019
14
The abnormal function of CD39+ regulatory T cells could be corrected by high-dose dexamethasone in patients with primary immune thrombocytopenia. 38
31154474 2019
15
Immune Thrombocytopenic Purpura in Pregnancy. 38
31418451 2019
16
Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia. 38
31377437 2019
17
Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. 38
31292909 2019
18
Patient characteristics when starting treatment and patterns of treatment in adults with chronic immune thrombocytopenia. 38
31433305 2019
19
Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment. 38
31422582 2019
20
Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis. 38
31423574 2019
21
Comments on and assessments of "Associations between FCGR polymorphisms and immune thrombocytopenia: A meta-analysis". 38
31419842 2019
22
Investigation of Dynamic Thiol/Disulfide Homeostasis in Children With Acute Immune Thrombocytopenia. 38
31033791 2019
23
[Protocol for the study and treatment of primary immune thrombocytopenia: PTI-2018]. 38
31178291 2019
24
Excessive expressions of T cell activation markers in pediatric immune thrombocytopenia. 38
31146120 2019
25
Immune Thrombocytopenia-A Disease or a Group of Disorders? Where Do We Stand in 2019? 38
31390662 2019
26
[Clinical Significance of Platelet Membrane Glycoprotein GPIIb/IIIa in Diagnosis and Treatment of Immune Thrombocytopenia]. 38
31418387 2019
27
Modifying risk factors of chronicity in children with immune thrombocytopenia: Still underway. 38
31327669 2019
28
Evaluation of IVIG response in relation to Th1/Th2 cytokines in pediatricm immune thrombocytopenia. 38
31129375 2019
29
[Treatment of ITP and AIHA in CVID: A systematic literature review]. 38
31101329 2019
30
[Research Progress on Immune Mechanism of Immune Thrombocytopenia--Review]. 38
31418400 2019
31
The prediction value of Treg cell subtype alterations for glucocorticoid treatment in newly diagnosed primary immune thrombocytopenia patients. 38
31323447 2019
32
Response to thrombopoietic agents is related to on-treatment bone marrow megakaryocyte morphology in patients with chronic immune thrombocytopenia. 38
31012979 2019
33
Clinical Efficacy and Safety of High-Dose Dexamethasone Plus Low-Dose Rituximab as First-Line Therapy in Newly Diagnosed Primary Immune Thrombocytopenia. 38
31388265 2019
34
Blood transcriptome and clonal T cell correlates of response and nonresponse to eltrombopag therapy in a cohort of patients with chronic immune thrombocytopenia. 38
31296576 2019
35
Successful implementation of an automated electronic support system for patient safety monitoring: The alemtuzumab in multiple sclerosis safety systems (AMS3) study. 38
29911471 2019
36
Thalidomide induce response in patients with corticosteroid-resistant or relapsed ITP by upregulating Neuropilin-1 expression. 38
31030100 2019
37
Autoimmunity in Common Variable Immunodeficiency. 38
31349011 2019
38
Smoldering Multiple Myeloma Presenting as Immune Thrombocytopenia. 38
31388276 2019
39
Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort. 38
31292991 2019
40
Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency. 38
30877075 2019
41
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. 38
31364154 2019
42
Involvement of Interferon-γ + 874A/T Polymorphism in the Pathogenesis of and Therapeutic Response to Immune Thrombocytopenia. 38
30955035 2019
43
Current and emerging treatments for immune thrombocytopenia. 38
31237783 2019
44
Research Progress on Chinese Medicine Immunomodulatory Intervention for Chronic Primary Immune Thrombocytopenia: Targeting Cellular Immunity. 38
31278626 2019
45
Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes. 38
30940614 2019
46
Association of Immune Thrombocytopenia and Interstitial Pneumonia. 38
31292378 2019
47
Acquired Glanzmann thrombasthenia: From antibodies to anti-platelet drugs. 38
31010659 2019
48
Multiple Autoimmune Disorders in Aicardi-Goutières Syndrome. 38
30898416 2019
49
Tissue Factor-Negative Cell-Derived Microparticles Play a Distinctive Role in Hemostasis: A Viewpoint Review. 38
31195421 2019
50
Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus. 38
31246559 2019

Variations for Thrombocytopenia Due to Platelet Alloimmunization

Expression for Thrombocytopenia Due to Platelet Alloimmunization

Search GEO for disease gene expression data for Thrombocytopenia Due to Platelet Alloimmunization.

Pathways for Thrombocytopenia Due to Platelet Alloimmunization

Pathways related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.3 THPO ITGB3 ITGA2B ITGA2 CD40LG CD4
2
Show member pathways
13.18 THPO SELP MPL ITGB3 ITGA2B ITGA2
3
Show member pathways
12.95 THPO ITGB3 ITGA2B ITGA2 FCGR2B FCGR2A
4
Show member pathways
12.1 ITGB3 ITGA2B ITGA2
5
Show member pathways
12.03 ITGB3 ITGA2B ITGA2 GP9
6 11.99 SELP CD40LG CD4
7 11.95 FCGR2B CD40LG CD19
8 11.95 ITGB3 ITGA2 FCGR2C FCGR2B FCGR2A
9
Show member pathways
11.91 FCGR2C FCGR2B FCGR2A
10
Show member pathways
11.91 ITGB3 ITGA2B ITGA2
11 11.89 ITGB3 FCGR2C FCGR2B FCGR2A
12 11.88 SELP FCGR2C FCGR2A
13 11.83 ITGB3 ITGA2B ITGA2 CD19
14 11.75 ITGB3 ITGA2B ITGA2 GP9 FCGR2A
15 11.69 ITGB3 ITGA2B ITGA2 FCGR2A
16 11.69 SELP FCGR2C FCGR2B FCGR2A
17 11.61 THPO ITGB3 ITGA2B ITGA2
18 11.59 ITGB3 FCGR2C FCGR2B FCGR2A
19 11.57 SELP ITGB3 CD40LG
20
Show member pathways
11.54 THPO MPL ITGB3 ITGA2B GP9
21 11.52 ITGB3 ITGA2B ITGA2
22 11.49 ITGB3 ITGA2B ITGA2 CD19
23 11.49 THPO ITGB3 ITGA2B ITGA2 GP9 CD4
24 11.48 CD40LG CD4 CD19
25 11.44 ITGB3 ITGA2B FCGR2A
26 11.4 ITGB3 ITGA2B GP9
27 11.33 ITGB3 ITGA2B ITGA2 GP9
28 11.29 THPO MPL ITGB3 ITGA2B ITGA2 FCGR2A
29 11.24 CD40LG CD4 CD19
30 11.09 ITGB3 ITGA2B
31 10.97 ITGB3 ITGA2B
32 10.91 THPO ITGB3 ITGA2B ITGA2 CD40LG
33 10.73 ITGA2 GP9

GO Terms for Thrombocytopenia Due to Platelet Alloimmunization

Cellular components related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.87 MPL ITGB3 ITGA2B ITGA2 CD40LG CD4
2 plasma membrane GO:0005886 9.8 SELP MPL ITGB3 ITGA2B ITGA2 GP9
3 integral component of plasma membrane GO:0005887 9.76 SELP ITGB3 GP9 FCGR2B CD40LG CD4
4 integrin complex GO:0008305 9.58 ITGB3 ITGA2B ITGA2
5 platelet alpha granule membrane GO:0031092 9.54 SELP ITGB3 ITGA2B
6 external side of plasma membrane GO:0009897 9.23 SELP ITGA2B ITGA2 FCGR2B CD40LG CD4
7 membrane GO:0016020 10.25 SELP MPL ITGB3 ITGA2B ITGA2 GP9
8 integral component of membrane GO:0016021 10.1 SELP MPL ITGB3 ITGA2B ITGA2 GP9

Biological processes related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.83 ITGB3 ITGA2 FCGR2B CD4
2 platelet degranulation GO:0002576 9.67 SELP ITGB3 ITGA2B
3 platelet activation GO:0030168 9.63 ITGB3 GP9 CD40LG
4 cell adhesion GO:0007155 9.63 SELP ITGB3 ITGA2B ITGA2 GP9 CD4
5 integrin-mediated signaling pathway GO:0007229 9.58 ITGB3 ITGA2B ITGA2
6 leukocyte cell-cell adhesion GO:0007159 9.54 SELP CD40LG
7 cell-matrix adhesion GO:0007160 9.54 ITGB3 ITGA2B ITGA2
8 cell adhesion mediated by integrin GO:0033627 9.51 ITGB3 ITGA2
9 cell-substrate adhesion GO:0031589 9.48 ITGB3 ITGA2
10 mesodermal cell differentiation GO:0048333 9.43 ITGB3 ITGA2
11 platelet aggregation GO:0070527 9.43 MPL ITGB3 ITGA2B
12 immune response GO:0006955 9.43 FCGRT FCGR2C FCGR2B CD40LG CD4 CCR6
13 thrombopoietin-mediated signaling pathway GO:0038163 9.32 THPO MPL
14 positive regulation of leukocyte migration GO:0002687 8.8 SELP ITGA2B ITGA2

Molecular functions related to Thrombocytopenia Due to Platelet Alloimmunization according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 virus receptor activity GO:0001618 9.33 ITGB3 ITGA2 CD4
2 fibrinogen binding GO:0070051 8.96 ITGB3 ITGA2B
3 IgG binding GO:0019864 8.92 FCGRT FCGR2C FCGR2B FCGR2A

Sources for Thrombocytopenia Due to Platelet Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....